Arianna Palladini

Pavia, 27100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Journal: JCO precision oncology

Published: January 29, 2026

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture.

Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture.

Journal: Biological research

Published: August 19, 2025

Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response.

Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response.

Journal: Frontiers in pharmacology

Published: July 29, 2025

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Journal: JCO precision oncology

Published: December 05, 2024

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Journal: Journal of translational medicine

Published: December 03, 2024

Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay.

Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay.

Journal: Methods in cell biology

Published: November 08, 2024

Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?

Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?

Journal: Cell communication and signaling : CCS

Published: August 18, 2024

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).

Journal: Journal of translational medicine

Published: August 03, 2024

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.

Journal: International journal of molecular sciences

Published: July 31, 2023

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors.

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors.

Journal: Frontiers in oncology

Published: March 06, 2023

Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.

Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.

Journal: Immunotherapy

Published: November 16, 2022

Showing 1-12 of 39

Last Updated: 09/26/2026